Unlocking the potential: phenylboronic acid as a nuclear-targeting boron agent for neutron capture therapy.
Med Oncol
; 41(5): 104, 2024 Apr 04.
Article
in En
| MEDLINE
| ID: mdl-38573420
ABSTRACT
It has been proposed that boron neutron capture therapy (BNCT) holds promise as a treatment modality for melanoma. However, the effectiveness of boron agents in delivery remains a critical issue to be addressed for BNCT. To this end, phenylboronic acid, which exhibits good water solubility and low cytotoxicity similar to BPA, has been investigated as a potential nuclear-targeting boron agent. The boron concentration of phenylboronic acid was found to be 74.47 ± 12.17 ng/106 B16F10 cells and 45.77 ± 5.64 ng/106 cells in the nuclei. Molecular docking experiments were conducted to investigate the binding of phenylboronic acid to importin proteins involved in nuclear transport. The potential of phenylboronic acid to serve as a desirable nucleus-delivery boron agent for neutron capture therapy in melanoma warrants further exploration.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Boronic Acids
/
Neutron Capture Therapy
/
Melanoma
Limits:
Humans
Language:
En
Journal:
Med Oncol
Journal subject:
NEOPLASIAS
Year:
2024
Document type:
Article
Affiliation country:
China